A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

3127

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight
Overweight or Obesity

Interventions

DRUG: Orforglipron
DRUG: Placebo

Sponsor

Eli Lilly and Company